Nine Point Two Capital LLC Prothena Corp Public LTD CO Transaction History

Nine Point Two Capital LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$48.26 - $78.59 $96,375 - $156,944	-1,997 Reduced 34.8%	3,741 $255,000
Q1 2023 May 15, 2023	BUY	$46.97 - $58.27 $269,513 - $334,353	5,738 New	5,738 $278,000
Q3 2022 Nov 14, 2022	BUY	$25.16 - $60.63 $21,914 - $52,808	871 Added 6.04%	15,290 $927,000
Q2 2022 Aug 15, 2022	BUY	$22.73 - $39.98 $66,939 - $117,741	2,945 Added 25.67%	14,419 $391,000
Q1 2022 May 16, 2022	BUY	$30.27 - $49.22 $160,491 - $260,964	5,302 Added 85.9%	11,474 $419,000
Q4 2021 Feb 11, 2022	BUY	$42.11 - $73.26 $259,902 - $452,160	6,172 New	6,172 $304,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $714M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Nine Point Two Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Nine Point Two Capital LLC with notifications on news.